Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interception of Minimal Residual Disease in Solid Malignancies

NCT07268469 is registered in ClinicalTrials.gov with European Institute of Oncology as lead sponsor.

NCT NCT07268469
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07268469 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interception of Minimal Residual Disease in Solid Malignancies
Lead sponsor
European Institute of Oncology
Phase
Not applicable
Overall status
Not yet recruiting
Start date
December 31, 2025
Completion date
July 31, 2033
Enrollment
840 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric cancer, high grade serous ovarian cancer, non small cell lung cancer, prostate cancer